Respiratory Failure, Sepsis
Conditions
Keywords
Sepsis, Respiratory failure
Brief summary
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.
Detailed description
This study investigates the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in patients with sepsis and respiratory failure. Sepsis is a common condition in hospital settings and is associated with high rates of morbidity and mortality and despite ongoing development in the treatment and supportive care of sepsis, mortality remains considerable. cfDNA/NET therapeutic apheresis with NucleoCapture is indicated for the treatment of sepsis and for the treatment/prevention of septic shock. Participants will be randomised to receive either standard of care (SOC) or SOC plus NucleoCapture treatment, SOC will be according to the current guidelines described by the Surviving Sepsis Campaign: international guidelines for the management of sepsis and septic shock. Participants in the SOC plus NucleoCapture arm will receive one treatment session with NucleoCapture per day, for the first three days. Each treatment session with NucleoCapture will last for up 6 hours, aiming to treat 4.5 plasma volumes. Treatment sessions with NucleoCapture treating less than 3.5 plasma volumes will be counted as incomplete and the treatment session will be repeated on the following day, up to day 5 maximum. Assessments and tests will take place for all participants whilst in Intensive Care Unit (ICU) on days 1 to 5, day 7, day 14, day 21 and day 28. Participants transferred to ward-based care before day 28 will receive no further study assessment visits from the point of transfer to ward-based care, apart from day 28 in which participants will receive a final study assessment visit.
Interventions
DEVICENucleoCapture device
100ml NucleoCapture selective DNA adsorber
Sponsors
ISS AG
Santersus AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants will be randomly assigned to either the interventional treatment arm (SOC plus NucleoCapture) or the SOC treatment arm in a 2:1
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients aged 18-75 * Proven or suspected respiratory sepsis aetiology * Acute respiratory failure currently requiring invasive mechanical ventilation for not more than 48 hours duration * Horowitz Index for Lung Function (Pa02/Fi02 Ratio) ≤200mmHg or ≤26.6kPa * Sequential organ failure assessment score (SOFA) ≥4 and ≤ 14 * Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).
Exclusion criteria
* Expected duration of invasive mechanical ventilation less than 48 hours * The use of other non-routine extracorporeal sepsis treatments such as very high flux renal replacement therapy (\>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc). * Presence of severe multiple organ failure at the point of enrolment as evidenced by: * Severe refractory vasoplegic failure * Norepinephrine dose \> 0.60 μg/kg/min * Use of epinephrine * Concomitant cardiogenic shock, clinically suspected or CI\<2.2 if measured * Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan * Coagulopathy as defined by platelet count \<50 * Calculated Plasma Volume greater than 5000ml as determined by an estimation of total blood volume (according to Nadler's formula, incorporating height, weight and sex) multiplied by (1- Haematocrit). A total blood volume calculator is available at https://www.omnicalculator.com/health/blood-volume * Long term oxygen therapy or home oxygen use * Liver cirrhosis (histologically proven or clinically suspected) * Active bleeding * Citrate intolerance if citrate is required for therapeutic apheresis * Heparin allergy if heparin is required for therapeutic apheresis * Metastatic disease with life expectancy of \<12 months and ECOG score of at least 2 * Haematological malignancy if not in remission * Solid organ transplant and concomitant use of immunosuppression * Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D) * Prior use of cardiopulmonary resuscitation (CPR) in index admission * Requirement for extracorporeal membrane oxygenation (ECMO) * Patient expected to die within 48 hours of admission to ICU * Known allergy to components of NucleoCapture * Current Participation in another interventional clinical trial * Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To demonstrate the NucleoCapture column reduces the amount of cfDNA/NETs in the plasma of participants with sepsis and respiratory failure | Within 6 hours from the baseline (pre-column) plasma | The mean reduction of an expected ≥50% of the net amount of cfDNA/NETs across the NucleoCapture column at the end of each NuceoCapture treatment session |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean reduction in circulating cfDNA/NETs measured by circulating blood levels of nucleosomes (H.3.1) | Before and after treatment with the NucleoCapture column and at the start and end of a 6 hour period in the SOC treatment arm | Mean relative reduction of circulating blood cfDNA/NETs at the end of a complete treatment session with NucleoCapture compared to the change in the mean levels of cfDNA/NETs over a 6 hour period in the SOC treatment arm |
| The clinical benefit of the NucleoCapture column in participants with sepsis and respiratory failure | From date of randomisation to day 21 for organ support and day 28 for survival | Change in organ support and survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| The biological efficacy and performance of NucleoCapture will be assessed using routine biomarkers | At baseline, days 1 to 5, day 7 and day 14 | Routine organ function, haematology, coagulation and inflammation biomarkers will be measured |
| The biological efficacy and performance of NucleoCapture will be assessed using non-routine biomarkers | At baseline, days 1 to 5, day 7 and day 14 | Non-routine biomarkers of inflammation and coagulation will be measured |
| Device handling and usability | Day 1 up to day 5 | Usability and handling of the device will be assessed in the intervention arm |
Countries
Germany, Switzerland, United Kingdom
Contacts
Primary ContactEmma Barsoum
Outcome results
None listed